Cellular Senescence in the Treatment of Ovarian Cancer.

about

Cellular Senescence in the Treatment of Ovarian Cancer.

Item

http://www.wikidata.org/entity/Q53692066

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Cellular Senescence in the Treatment of Ovarian Cancer.

@en

Cellular Senescence in the Treatment of Ovarian Cancer.

@nl

type

Item

label

Cellular Senescence in the Treatment of Ovarian Cancer.

@en

Cellular Senescence in the Treatment of Ovarian Cancer.

@nl

prefLabel

Cellular Senescence in the Treatment of Ovarian Cancer.

@en

Cellular Senescence in the Treatment of Ovarian Cancer.

@nl

P1476

Cellular Senescence in the Treatment of Ovarian Cancer.

@en

P2093

Congjian Xu

http://www.w3.org/2001/XMLSchema#string

Haiou Liu

http://www.w3.org/2001/XMLSchema#string

Zehua Wang

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-NoDerivatives

P2860

Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling

A biomarker that identifies senescent human cells in culture and in aging skin in vivo

Kruppel-like factor 4 mediates p53-dependent G1/S cell cycle arrest in response to DNA damage

Cellular senescence in aging and age-related disease: from mechanisms to therapy

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.

The serial cultivation of human diploid cell strains

Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells.

Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study.

Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease

Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III--the OVAR-IMRT-02 Study.

P304

895-902

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1097/IGC.0000000000001257

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29688903

http://www.w3.org/2001/XMLSchema#string

P921

ovarian neoplasm

ovarian cancer

carcinoma

P932

5976218

http://www.w3.org/2001/XMLSchema#string